A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
- Conditions
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT04880031
- Locations
- 🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸Arizona Liver Health, Tucson, Arizona, United States
🇺🇸Liver Institute PPLC, Tucson, Arizona, United States
Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT04514237
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT04221906
- Locations
- 🇩🇪
Gemeinschaftspraxis Dr. med. Johannes Niesmann und Dr. med. Nick Othlinghaus Hauszentrum im Jahrhunderthaus - Zentrum für klinische Studien, Bochum, Germany
🇩🇪bioskin GmbH, Hamburg, Germany
🇩🇪Klinische Forschung Schwerin GmbH, Schwerin, Germany
Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT04163263
- Locations
- 🇺🇸
Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸International Clinical Research, Sanford, Florida, United States
🇨🇦Innovaderm Research, Inc., Montreal, Canada
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
- Conditions
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT03977155
- Locations
- 🇺🇸
Clinical Research Associates, Huntsville, Alabama, United States
🇺🇸Synexus Clinical Research US, Inc. - Phoenix Southeast, Chandler, Arizona, United States
🇺🇸Pinnacle Research Group, Anniston, Alabama, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT03960450
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia
🇦🇺Sinclair Dermatology, East Melbourne, Australia
🇦🇺Linear, Nedlands, Australia
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 117
- Registration Number
- NCT03780517
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut Bergonié, Bordeaux, France
🇰🇷Chungbuk National University Hospital, Cheongju-si, Korea, Republic of
Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT03464058
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 143
- Registration Number
- NCT03371251
- Locations
- 🇦🇷
Hospital Militar Central - Servicio de ReumatologÃa, Ciudad Autonoma de Buenos Aires, Argentina
🇦🇷Centro Medico Privado de Reumatologia, San Miguel De Tucumán, Argentina
🇦🇷Centro de Investigaciones Reumatologicas, San Miguel De Tucumán, Argentina
Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT03328494
- Locations
- 🇬🇧
Edinburgh Cancer Centre - Western General Hospital, Edinburgh, United Kingdom
🇬🇧Addenbrooks Hospital, Cambridge, United Kingdom
🇬🇧Royal Marsden, London, United Kingdom